non glp-1 drugs for weight loss A new UGA-led meta-analysis compared the three FDA-approved medications used in non-diabetic patients. Researchers found that tirzepatide was associated with the greatest weight reduction, with participants losing more Rx Trends: Real-World Data on

Cardiovascular outcome trials (CVOTs) of GLP-1RAs To date, the REWIND study has demonstrated for the first time that primary cardiovascular prevention strategies can significantly reduce cardiovascular adverse events in patients with T2DM, regardless of whether or not these patients are co-diagnosed with CVD [23]

Phase III studies are ongoing to further investigate the efficacy and safety of survodutide in obesity management

Those real outcomes drive our conservative, measured approach

Juli-Romero C, Palau-Mart C, Tejedor-Bosqued A

Research on Eli Lillys orforglipron is ongoing, so efficacy data isnt available yet

[On-screen text: Questions